Evaluating the evolving evidence: The challenges of molecular-targeted therapy in management of gastric cancer


Over the past decade, a multitude of molecular targeted agents have been explored in the treatment of advanced metastatic gastric. Recent advances in molecular signaling pathways that are dysregulated in gastric cancer lead to the development of new targeted therapies for the treatment of advanced and metastatic gastric cancer. The addition of trastuzumab to first-line chemotherapy is now a standard of care for the treatment of Human epidermal growth factor receptor (HER2-) positive advanced or metastatic disease, and other HER2-targeted therapies are in late-stage clinical development. Findings from recent major clinical trials provide important insight into the future of metastatic gastric cancer management, which may include the use of anti-angiogenesis, Mesenchymal epithelial transition factor (MET) and Hedgehog Pathways Inhibitortherapy across multiple treatment lines, in the salvage setting, and as part of novel regimens in combination with other targeted agents.

Share and Cite:

Ahmed, Y. and Ali, M. (2014) Evaluating the evolving evidence: The challenges of molecular-targeted therapy in management of gastric cancer. Open Journal of Gastroenterology, 4, 6-15. doi: 10.4236/ojgas.2014.41002.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] National Comprehensive Cancer Network (2013) NCCN clinical practice guidelines in oncology (NCCN Guidelines®): Gastric cancer, version 2. www.nccn.org
[2] Smyth, E.C. and Cunningham, D. (2012) Targeted therapy for gastric cancer. Current Treatment Options in Oncology, 13, 377-389.
[3] Guggenheim, D.E. and Shah, M.A. (2013) Gastric cancer epidemiology and risk factors. Journal of Surgical Oncology, 107, 230-236.
[4] Price, T.J., Shapiro, J.D., Segelov, E., et al. (2012) Management of advanced gastric cancer. Expert Review of Gastroenterology & Hepatology, 6, 199-208; quiz 209.
[5] DeVita, F., Giuliani, F., Silvestris, N., et al. (2012) Current status of targeted therapies in advanced gastric cancer. Expert Opinion on Therapeutic Targets, 16, S29-S34.
[6] Begnami, M.D., Fukuda, E., Fregnani, J.H., et al. (2011) Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. Journal of Clinical Oncology, 29, 3030-3036.
[7] Yamashita-Kashima, Y., Iijima, S., Yorozu, K., et al. (2011) Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clinical Cancer Research, 17, 5060-5070.
[8] Lordick, F., Kang, Y.K., Chung, H.C., et al. (2013) Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): A randomised, open-label phase 3 trial. Lancet Oncology, 14, 490-499.
[9] Waddell, T., Chau, I., Cunningham, D., et al. (2013) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial. Lancet Oncology, 14, 481-489.
[10] Boku, N. (2013) HER2-positive gastric cancer. Gastric Cancer, 17, 1-12.
[11] Bang, Y.-J., Van Cutsem, E., Feyereislova, A., et al. for ToGA Trial Investigators (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): A phase 3, openlabel, randomised controlled trial. Lancet, 376, 687-697.
[12] Herceptin [package insert]. (2010) South San Francisco, CA: Genentech, Inc.
[13] Perjeta [package insert]. (2012) South San Francisco, CA: Genentech, Inc.
[14] Clinical Trials.gov. (2013) A study of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy in patients with HER2-positive metastatic gastroesophageal junction or gastric cancer.
[15] Verma, S., Miles, D., Gianni, L., et al. for the EMILIA Study Group (2012) Trastuzumab emtansine for HER2positive advanced breast cancer. New England Journal of Medicine, 367, 1783-1791.
[16] Kadcyla [package insert]. (2013) South San Francisco, CA: Genentech, Inc.
[17] Clinical Trials.gov. (2013) A study of trastuzumab emtansine versus taxane in patients with advanced gastric cancer. http://clinicaltrials.gov/ct2/show/NCT01641939
[18] Clinical Trials.gov. (2013) A combination study of trastuzumab emtansine and capecitabine in patients with breast cancer or gastric cancer.
[19] Hecht, J.R., Bang, Y.-J., Qin, S., et al. (2013) Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. Journal of Clinical Oncology, 31, abstr LBA4001.
[20] Bang, Y.-J., Ruihua, X., Taroh, S., et al. (2013) A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer in Asian population: TyTAN study. 2013 Gastrointestinal Cancers Symposium, San Francisco, 24-26 January 2013.
[21] Ohtsu, A., Shah, M.A., Van Cutsem, E., et al. (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology, 29, 3968-3976.
[22] Kang, J.H., Lee, S.I., Lim do, H., et al. (2012) Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. Journal of Clinical Oncology, 30, 1513-1518.
[23] Kim, S.E., Shim, K.N., Jung, S.A., Yoo, K. and Lee, J.H. (2009) The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer. Gut and Liver, 3, 88-94. http://dx.doi.org/10.5009/gnl.2009.3.2.88
[24] Maeda, K., Chung, Y.S., Ogawa, Y., et al. (1996) Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer, 77, 858-863.
[25] Van Cutsem, E., De Haas, S., Kang, Y.K., et al. (2012) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trial. Journal of Clinical Oncology, 30, 2119-2127.
[26] Maru, D., Venook, A.P. and Ellis, L.M. (2013) Predictive biomarkers for bevacizumab: Are we there yet? Clinical Cancer Research, 19, 2824-2827.
[27] Reichert, J.M. (2013) Antibodies to watch in 2013: Midyear update. MAbs, 5, 513-517.
[28] Fuchs, C.S., Tomasek, J., Cho, J.Y., et al. (2013) REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinumand/or fluoropyrimidine-containing combination therapy. Journal of Clinical Oncology, 31, abstr LBA5.
[29] Tabernero, J., Tomasek, J., Filip, D., et al. (2013) REGARD phase 3, randomized trial of ramucirumab in patients with metastatic gastric or GEJ adenocarcinoma following progression on first-line chemotherapy. Annals of Oncology, 24, iv14.
[30] Ford, H., Marshall, A., Wadsley, J., et al. (2013) Cougar-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. Journal of Clinical Oncology, 30, abstr LBA4.
[31] Wesolowski, R., Lee, C. and Kim, R. (2009) Is there a role for second-line chemotherapy in advanced gastric cancer? The Lancet Oncology, 10, 903-912.
[32] Cervantes, A., Roda, D., Tarazona, N., Roselló, S. and Pérez-Fidalgo, J.A. (2013) Current questions for the treatment of advanced gastric cancer. Cancer Treatment Reviews, 39, 60-67.
[33] Clinical Trials.gov. (2013) A study of paclitaxel with or without ramucirumab in metastatic gastric adenocarcinoma (RAINBOW).
[34] Graziano, F., Galluccio, N., Lorenzini, P., et al. (2011) Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. Journal of Clinical Oncology, 29, 4789-4795.
[35] Huang, T.J., Wang, J.Y., Lin, S.R., Lian, S.T. and Hsieh, J.S. (2001) Overexpression of the c-met protooncogene in human gastric carcinoma—Correlation to clinical features. Acta Oncologica, 40, 638-643.
[36] Iverson, T., Donehower, R.C., Davidenko, I., et al. (2011) Safety and efficacy of epirubicin, cisplatin and capecitabine (ECX) plus rilotumumab (R) as first-line treatment for unresectable locally advanced (LA) or metastatic (M) gastric or esophagogastric junction (EGJ) adenocarcinoma. European Journal of Cancer, 47, S443.
[37] Oliner, K.S., Tang, R., Anderson, A., et al. (2012) Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. Journal of Clinical Oncology, 30, abstr 4005.
[38] Clinical Trials.gov. (2013) First-line treatment for locally advanced or metastatic mesenchymal epithelial transition factor (MET)-positive gastric, lower esophageal, or gastroesophageal junction (GEJ) adenocarcinoma (RILOMET-1). http://clinicaltrials.gov/show/NCT01697072
[39] Surati, M., Patel, P., Peterson, A. and Salgia, R. (2011) Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opinion on Biological Therapy, 11, 1655-1662.
[40] Catenacci, D.V.T., Henderson, L., Xiao, S.-Y., et al. (2011) Durable complete response of metastatic gastric cancer with anti-met therapy followed by resistance at recurrence. Cancer Discovery, 1, 573-579.
[41] Clinical Trials.gov. (2013) A study of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive gastroesophageal cancer (MetGastric).
[42] McMillan, R. and Matsui, W. (2012) Molecular pathways: The hedgehog signaling pathway in cancer. Clinical Cancer Research, 18, 4883-4888.
[43] Ng, J.M.Y. and Curran, T. (2011) The hedgehog’s tale: Developing strategies for targeting cancer. Nature Reviews Cancer, 11, 493-501.
[44] Hui, C. and Angers, S. (2011) Gli proteins in development and disease. Annual Review of Cell and Developmental Biology, 27, 513-537.
[45] Erivedge [package insert]. (2012) South San Francisco, CA: Genentech, Inc.
[46] Martin, J., Donnelly, J.M., Houghton, J.M. and Zavros, Y. (2010) The role of sonic hedgehog reemergence during gastric cancer. Digestive Diseases and Sciences, 55, 1516-1524. http://dx.doi.org/10.1007/s10620-010-1252-z
[47] Cohen, D.J., Christos, P.J., Kindler, H.L., et al. (2013) Vismodegib (V), a hedgehog pathway inhibitor, combined with FOLFOX for the first-line therapy of patients (pts) with advanced gastric cancer and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study. Journal of Clinical Oncology, 21, abstr 4011.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.